A non-opioid analgesic implant for sustained post-operative intraperitoneal delivery of lidocaine, characterized using an ovine model.


Journal

Biomaterials
ISSN: 1878-5905
Titre abrégé: Biomaterials
Pays: Netherlands
ID NLM: 8100316

Informations de publication

Date de publication:
12 2020
Historique:
received: 26 03 2020
revised: 11 09 2020
accepted: 18 09 2020
pubmed: 26 9 2020
medline: 15 5 2021
entrez: 25 9 2020
Statut: ppublish

Résumé

Appropriate management of post-operative pain is an ongoing challenge in surgical practice. At present, systemic opioid administration is routinely used for analgesia in the post-operative setting. However, due to significant adverse effects and potential for misuse, there is a perceived need for the development of alternative, opioid-sparing treatment modalities. Continuous infusion of local anesthetic into the peritoneum after major abdominal surgery reduces pain and opioid consumption, and enhances recovery from surgery. Here we describe a non-opioid, poly(ethylene-co-vinyl-acetate) intraperitoneal implant for the sustained delivery of local anesthetic following major abdominal surgery. A radio-opaque core had the required mechanical strength to facilitate placement and removal procedures. This core was enclosed by an outer shell containing an evenly dispersed local anesthetic, lidocaine. Sustained release of lidocaine was observed in an ovine model over days and the movement modelled between peritoneal fluid and circulating plasma. While desirably high levels of lidocaine were achieved in the peritoneal space these were several orders of magnitude higher than blood levels, which remained well below toxic levels. A pharmacokinetic model is presented that incorporates in vitro release data to describe lidocaine concentrations in both peritoneal and plasma compartments, predicting similar release to that suggested by lidocaine concentrations remaining in the device after 3 and 7 days in situ. Histological analysis revealed similar inflammatory responses following implantation of the co-extruded implant and a commercially used silicone drain after three days. This non-opioid analgesic implant provides sustained release of lidocaine in an ovine model and is suitable for moving onto first in human trials.

Identifiants

pubmed: 32977258
pii: S0142-9612(20)30655-4
doi: 10.1016/j.biomaterials.2020.120409
pii:
doi:

Substances chimiques

Analgesics, Non-Narcotic 0
Analgesics, Opioid 0
Anesthetics, Local 0
Lidocaine 98PI200987

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

120409

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Darren Svirskis (D)

School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand. Electronic address: d.svirskis@auckland.ac.nz.

Georgina Procter (G)

School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom.

Manisha Sharma (M)

School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Prabhat Bhusal (P)

School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Anusha Dravid (A)

School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Wiremu MacFater (W)

South Auckland Clinical School, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Ahmed Barazanchi (A)

South Auckland Clinical School, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Laura Bennet (L)

Department of Physiology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Kaushik Chandramouli (K)

School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Sree Sreebhavan (S)

Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Priyanka Agarwal (P)

School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Satya Amirapu (S)

School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Jacqueline A Hannam (JA)

Department of Pharmacology & Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Gavin P Andrews (GP)

School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom.

Andrew Hill (A)

South Auckland Clinical School, Faculty of Medical and Health Sciences, University of Auckland, Private Bag, 92019, Auckland, New Zealand.

David S Jones (DS)

School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH